Precision Oncology Startup Gains Global Momentum After Securing CHF 85 Million in Series C Funding

In a quiet corner of the Technopark Zurich campus in Schlieren, a team of 120 scientists and engineers is working on something that could fundamentally change how oncologists approach cancer treatment. CellGenix, a precision oncology company that only recently shifted its operational hub from Basel to the Zurich region, announced last week that it has closed a CHF 85 million Series C funding round led by international biotech investors, marking a significant milestone for Switzerland's innovation ecosystem.

The company's breakthrough centres on an algorithmic platform that analyses individual tumour mutations and predicts which patients will respond best to specific therapies—potentially eliminating months of trial-and-error treatment. Unlike traditional cancer care, where clinicians often resort to sequential drug attempts, CellGenix's approach promises to match therapy to biology from day one.

"We're seeing uptake across major European hospital networks," the company disclosed in a statement, noting that its technology is already being piloted at Universitätsspital Zurich and several major German cancer centres. The platform integrates genomic sequencing with machine learning models trained on over 50,000 patient records—a dataset advantage that positions CellGenix ahead of many competitors clustered around Boston or the San Francisco Bay Area.

The Schlieren relocation is telling. The Technopark site, which hosts over 800 companies across life sciences, software, and advanced manufacturing, has emerged as Switzerland's answer to Cambridge or Basel's pharmaceutical corridor. Rent at the facility averages CHF 220 per square metre annually—significantly cheaper than central Zurich's Europaplatz district, where prime office space commands CHF 400 and upward. Yet proximity to USZ, ETH, and Zurich's financial networks makes it an ideal compromise for biotech firms scaling operations.

The funding also underscores a broader pattern: Switzerland's tech sector is diversifying beyond fintech and software. According to the most recent Innovation Index data, life sciences and healthtech now account for nearly 22% of venture investment in the region—a jump from 14% five years ago. CellGenix joins companies like Sophia Genetics and Hemo Sapiens in a growing wave of deeptech startups leveraging Switzerland's strengths in precision engineering and regulatory credibility.

What sets CellGenix apart is timing. As governments worldwide push for value-based healthcare and insurance companies demand better outcomes data, platforms that can reduce treatment failures and hospitalisation rates are increasingly attractive to hospital systems constrained by budget pressures. For Zurich's tech ecosystem, it's a validation that innovation isn't limited to fintech anymore.

This article was compiled by AI and screened before publishing. See our editorial standards.